ProfileGDS5678 / 1460695_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 89% 92% 90% 90% 93% 92% 89% 91% 90% 92% 91% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.414591
GSM967853U87-EV human glioblastoma xenograft - Control 27.1135589
GSM967854U87-EV human glioblastoma xenograft - Control 37.5839692
GSM967855U87-EV human glioblastoma xenograft - Control 47.3265690
GSM967856U87-EV human glioblastoma xenograft - Control 57.3815590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6558393
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4173992
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.049389
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4692291
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3173990
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6592192
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4656791
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.654592
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5104992